The mast cell in innate and adaptive immunity.
The mast cell in innate and adaptive immunity.
复制标题
DOI：
10.1007/978-1-4419-9533-9_10
复制
发表时间：
2011
影响因子：
--
通讯作者：
C. Shelburne;S. Abraham
中科院分区：
文献类型：
--
作者：
C. Shelburne;S. Abraham
肥大细胞（MC）曾经被认为是致病性IgE和IgG介导的反应，如变态反应的效应细胞。然而，过去15年的发展表明，MC在脊椎动物中已经进化为有益的效应细胞，参与感染期间产生的最初炎症反应。这种促炎环境已被证明是重要的启动先天性反应在许多不同的感染模型，最近，在适应性免疫的发展以及。有趣的是，后一发现导致发现小MC活化化合物可以在疫苗制剂中充当佐剂。因此，我们在感染性疾病背景下对MC的持续理解可能不仅会扩大我们在正常免疫过程中的MC范围，而且会提供新的治疗靶点来对抗疾病。
Mast cells (MCs) were once considered only as effector cells in pathogenic IgE- and IgG-mediated responses such as allergy. However, developments over the last 15 years have suggested that MCs have evolved in vertebrates as beneficial effector cells that are involved in the very first inflammatory responses generated during infection. This pro-inflammatory environment has been demonstrated to be important for initiating innate responses in many different models of infection and more recently, in the development of adaptive immunity as well. Interestingly this latter finding has led to the discovery that small MC-activating compounds can behave as adjuvants in vaccine formulations. Thus, our continued understanding of the MC in the context of infectious disease is likely to not only expand our scope of the MC in the normal processes of immunity, but provide new therapeutic targets to combat disease.